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Parameter Baseline Follow-up (d)
m PCWP (mmHg) 18.8 14.3 (30)
(n¼5)
m RAP (mmHg) 11.5 12 (30)
n¼4
RVSP (mmHg) 49.5 52.5 (30)
n¼4
6 MWD (m) 318.5 343.3 (90)
n¼4
NT-Pro-BNP (pmol/L) 294.4 237 (90)
n¼4
MLWHF score 41.8 32.3 (90)
n¼4







SConclusions: This initial data demonstrates that the shunt device can be safely
implanted and early clinical improvement can be obtained in patients with heart failure
and preserved or mildly reduced ejection fraction. Longer term follow-up is warranted.Antiplatelets and Antithrombins
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No beneﬁt of Clopidogrel Pretreatment in stable patients undergoing elective PCI
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Jean-philippe collet5, Francois Bernasconi6, Gilles Montalescot7
1CH La Fontonne Antibes, Antibes, France, 2Pitié Salpétrière Hospital, Paris,
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Background: Although Clopidogrel pretreatment is recommended (class I-C) for stable
CAD patients scheduled for elective PCI, the beneﬁt of this strategy compared to an
administration at the time of PCI has not been shown on hard clinical outcome. We per-
formed a systematic review and meta-analysis of all RCTs to evaluate the impact of clo-
pidogrel pretreatment on mortality and major bleeding after elective PCI for stable CAD,
as compared with no pretreatment. An additional metaanalysis was done on registries.
Methods: We included studies on elective PCI from MEDLINE, EMBASE, CCTR
databases that reported clinical data on mortality and major bleeding. A random-effect
model was applied. Pretreatment was deﬁned as the administration of clopidogrel
before PCI. The primary efﬁcacy and safety endpoints were all-cause mortality and
major bleeding, respectively. Secondary endpoints included MACE, MI, Stroke,
UVR, Stent Thrombosis (ST), minor and any bleeding.
Results: Of the 392 titles identiﬁed, 6 (3 RCTs and 3 observational) met the inclusion
criteria, published between Aug-2004 and Dec-2012. Of 13628 patients, 1636 were
from RCTs. 55% underwent PCI. Results from the analysis of RCTs are shown in
Figure I. ST, stroke and UVR were not different between groups. In the analysis of
observational data, there was no difference between groups for all cause death, MI and
ST, nor in bleeding. Only MACE and UVR were decreased.B44 JACC Vol 62/18/Suppl B j October 27–NovemConclusions: Clopidogrel pretreatment is not associated with a reduction of mortality,
MACE or ischemic endpoints in stable CAD scheduled for elective PCI, but with an
excess of minor and any bleeding.
TCT-138
Clopidogrel Pretreatment in Non ST Elevation Acute Coronary Syndroms: no
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Background: Clopidogrel pretreatment is recommended for the treatment of
NSTEACS patients (class I-B), at a time when the ﬁnal revascularization strategy is
not known. A previous meta-analysis focused on randomized trials suggested a tiny
beneﬁt in patients undergoing PCI. We performed a new meta-analysis of not only
RCTs but also registries to assess the impact of clopidogrel pretreatment in NSTEACS
patients. We evaluated the global effect independently of revascularization ("All"
analysis) and in patients undergoing PCI ("PCI" analysis).
Methods: We included studies on NSTEACS from MEDLINE, EMBASE, CCT and
Biomedcentral. A random-effect model was applied. Pretreatment was deﬁned as the
administration of clopidogrel before PCI or catheterization. Primary efﬁcacy and
safety endpoints were all-cause mortality and major bleeding respectively, at longest
follow up available. Secondary endpoints included Major Adverse Cardiac Events
(MACE), Stroke, Stent Thrombosis, UVR.
Results: Of the 393 titles identiﬁed, 6 articles (3 RCTs and 3 observational studies)
met the inclusion criteria, published between August 2004 and January 2013,
including 28 350 patients, in those 14 678 from RCTs. 52% underwent PCI. Among
NSTEACS patients, clopidogrel pretreatment was not associated with a lower risk of
mortality ("all": OR¼0,85, 95%CI(0,66-1,08), p¼0,18 or "PCI": OR¼0,81, 95%
CI(0,58-1,13), p¼0,22). When considering all of studies (RCTs and registries)
together, the reduction in Ischemic endpoints (OR¼0,81, 95%CI(0,7-0,94), p¼0,006)
is counterbalanced by an increase in major bleeding (OR¼1,28, 95%CI(1,12-1,46),
p¼0,0002). The reduction in ischemic endpoints is no more signiﬁcant in the "PCI"
analysis (OR¼0,82, 95%CI(0,65-1,03), p¼0,10) while there is still an excess of major
bleeding in these patients (OR¼1,2, 95%CI(1-1,44), p¼0,048). ST, stroke and UVR
were not different between groups (pretreatment vs. no) in both analyses.
Conclusions: Clopidogrel pretreatment is not associated with a reduction of mortality
in NSTEACS patients; the reduction of MACE is counterbalanced by major bleeding
for "all" and "PCI" patients. The concept of systematic pretreatment in NSTE-ACS
patients needs reappraisal in the contemporary era.
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The effect of glycoprotein IIb/IIIa inhibitors on mortality and MACE following
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Background: Meta-analyses of PCI in NSTEMI/UA have shown GPIIbIIIa inhibitors
to be associated with a reduction in major adverse cardiac events at 30 days. However,
many of the trials were carried out before the routine use P2Y12 inhibitors which act
up-stream of GPIIbIIIa mediated platelet aggregation. Studies performed in the clo-
pidogrel yield conﬂicting results and registry data indicates that these agents are less
safe than trials would indicate.
Methods: We undertook an observational study at an interventional cardiology center
involving 5,227 patients undergoing PCI for NSTEMI/UA and receiving clopidogrel
and aspirin. GPIIbIIIa use was at the discretion of the operator. Primary outcome was
all cause mortality assessed at a median follow up of 4.6 years (IQR 3.0 - 6.2 years).
Results: 43.6% of patients were treated with GP IIb/IIIa inhibitors. The patients were
younger, more likely to be male, and have fewer comorbidities including previous MI,
CKD and PVD. They were less likely to suffer multivessel disease and more likely to
have a successful angiographic result. Kaplan-Meier analysis showed GP IIbIIIa
inhibitor use was associated with improved survival (p<0.001) and reduced MACE
(p¼0.011), but increased bleeding (p¼0.001). On multivariate analysis the beneﬁts
were lost for both survival (HR 0.876; 95% CI 0.693 – 1.108; p¼0.501) and MACE
(HR 1.036; 95% CI 0.883 – 1.216).ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins







SConclusions: Whilst GpIIb/IIIa inhibitor use was associated with a signiﬁcant
protective effect on Kaplan–Meier survival analysis, this disappeared when the
signiﬁcant baseline disparities seen in these patients were accounted for.
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Prospective Multicenter Registry of 6 Months Dual Antiplatelet Therapy after
new Generation Drug-eluting Stent Implantation: ESTROFA-DAPT Study.
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Background: Drug-eluting stents (DES) have been related to a certain risk of late
thrombosis. The recommended duration of dual antiplatelet therapy (DAPT) with DES
is 12 months. DAPT is not free from complications and is expensive. Trials with
limited size suggest that a 6 month DAPT period could be enough with new gener-
ation DES. There are no prospective clinical registries assessing the safety of such
approach.
Methods: All consecutive patients treated with a new generation DES (Xience V,
Xience Prime, Endeavor Resolute, Promus Element, Biomatrix, Nobori, Osiro) were
prospectively included in 20 different centers. Patients had to fulﬁll one of the
following inclusion criteria in order to have 6 month DAPT period prescribed: silent
ischemia, stable angina, low risk non-ST segment elevation myocardial infarction or
acute coronary syndrome where 12 months DAPT was discarded due to high bleeding
risk. Taking advantage of the ESTROFA-2 database (4,768 patients treated with new
generation DES, 4355 of them with 12 months DAPT) we will perform a propensity
score matching of the six months DAPT from the ESTROFA-DAPT registry with the
12 months DAPT from the ESTROFA-2 registry.
Results: A total of 800 patients have been included so far in 20 centers. The baseline
characteristics of the matched groups and the 1 year follow up results of the ﬁrst 500
patients would be presented at the meeting sessions.
Conclusions: The ESTROFA-DAPT registry will provide data regarding safety of a 6
month DAPT period after new generation DES implantation.
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The Disutility of Nuisance Bleeding: Insights from the TRANSLATE ACS
Registry
Amit Amin1, Tracy Y. Wang2, Lisa A. McCoy3, Richard G. Bach4, Eric Peterson5,
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Background: Prolonged dual anti-platelet therapy (DAPT) is recommended after an
acute coronary syndrome (ACS) to reduce ischemic events, but is associated with
increased rates of major and minor bleeding. The incidence of even lesser degrees of
'nuisance' bleeding on DAPT and its impact on quality of life (QOL) are largely
unknown.
Methods: We studied 9290 ACS patients from the TRANSLATE ACS study who
were treated with PCI and discharged alive between April 2010 to Sept 2012.
Bleeding post-hospital discharge was deﬁned via the BARC bleeding deﬁnitions. Our
primary outcome was the 6 month EQ-5D index score, based on the U.S. population
preference weights. The EQ5D visual analog scale (VAS) at 6 months was
a secondary outcome. To determine the association between nuisance bleeding and 6-
month QOL, we ﬁt a mixed-effects linear regression model for 6 month EQ5D index
adjusting for baseline EQ5D index, with site as random effect (hierarchical model) and
other confounders of the relationship between bleeding and health status. We ﬁt
a similar model for EQ5D visual analog scale (VAS).
Results: Of the 9,290 patients with ACS (mean age 61, 73% males, 89% Whites),
4134 (44.5%) underwent immediate PCI for STEMI, and 4308 (46.4%) underwent
PCI for non-STEMI. A total of 849 (9.1%) patients experienced BARC I type
nuisance bleeding. Those who experienced BARC I bleeding had lower scores on all 5
EQ5D domains (mobility, self-care, usual activities, pain and anxiety) and had a lower
5 point EQ5D VAS score. After adjustment for confounders, nuisance bleeding by 6
month was independently associated with a decrement in QOL at 6 month (-2.04JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrpoints on EQ5D VAS; 95% CI -0.93 to -3.15, P<0.001). Based on the EQ5D index
score, the utility decrement associated with nuisance bleeding was 0.026, 95% CI
0.015 to 0.037, P-value <0.001.
Conclusions: In TRANSLATE-ACS, we found that BARC Type I (nuisance)
bleeding occurred in 1 of 10 patients after an ACS event and was associated with
worse 6-month quality of life and utility. These ﬁndings suggest that even nuisance
bleeds are relevant to patients and deserve greater attention in clinical recommenda-
tions for treatment and future clinical trials of prolonged DAPT therapies.
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elderly - Results from the GENERATIONS trial, a pharmacodynamic study in
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Background: Platelet surface P-selectin and activated GPIIb-IIIa are markers of
platelet activation, degranulation and aggregation. In the TRITON trial prasugrel
(Pras) 10 mg reduced ischemic events vs. clopidogrel (Clop) 75 mg but increased
bleeding, notably in very elderly (VE) patients. Pras 5 mg is a treatment option in VE
patients but data on its effect on GPIIb-IIIa and P-selectin expression is lacking. We
performed a blinded, three-period cross-over study in stable CAD patients 75 y (VE)
or 45-65 y (NE) examining expression of these biomarkers following Pras (5 or 10
mg) and Clop 75 mg.
Methods: After a run-in on low dose aspirin, VE subjects (n¼23, 78  5 y) and NE
subjects (n¼22, 55  5 y) were randomized to Pras (5 or 10 mg) or Clop 75 mg during
three 12-day periods. ADP (20 mM)-stimulated platelet P-selectin and GPIIb-IIIa
(PAC-1) were measured by ﬂow-cytometry at baseline and at the end of each12-day
dosing period.
Results: PAC-1 and P-selectin (data not shown) expression after stimulation with 20
mM ADP did not differ between VE and NE at baseline or after any treatment period
(Figure). PAC-1 expression was signiﬁcantly reduced by pras 5 mg in both VE
(p<0.01) and NE (p<0.05). In the VE the 5 mg dose had similar effect as pras 10 mg.
Clop 75 mg did not signiﬁcantly reduce PAC-1 in VE. P-selectin expression showed
a similar proﬁle (data not shown).Conclusions: As assessed by GPIIb-IIIa and P-selectin in stable CAD patients, Pras 5
mg signiﬁcantly reduced ADP-induced platelet activation in the VE.
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Background: Increasingly cardiologists need to place coronary artery disease patients
implanted with drug-eluting stents on dual antiplatelet therapy (DAPT) regimens of
durations shorter than the 6-12 months recommended in current guidelines. Unfor-
tunately, no sufﬁcient clinical data are available to support such shorter DAPT
durations.
Methods: This prospective, nonrandomized, multicenter, controlled study of the
Endeavor zotarolimus-eluting stent (E-ZES) in real world Japanese patients consists of
two arms: patients who were enrolled at 106 medical institutions to receive DAPT for
3 months and then followed for 1year, and a 12-month DAPT arm consisting of
patients consecutively extracted from patients enrolled in the Endeavor Japan post-
marketing surveillance. The analysis was done on an intent to treat basis. Theacts/POSTER/Antiplatelets and Antithrombins B45
